A Prospective, Multicenter, Single-Arm Study on the Combination of Orelabrutinib and Rituximab in the Second-Line Treatment of Relapsed/Refractory Marginal Zone Lymphoma

Orelabrutinib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Who Are Intolerant to Prior Bruton Tyrosine Kinase Inhibitors (BTKi): Updated Results from a Phase 2 Study

Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma

Preliminary Data on the Efficacy and Safety of Orelabrutinib Combined with Rituximab and Methotrexate (ORM Regimen) As First-Line Treatment for Primary Central Nervous System Lymphoma, and the Exploration of Cerebrospinal Fluid Ctdna Dynamic Monitoring

Preliminary Efficacy of Orelabrutinib Targeted Therapy in Induction Therapy of Primary Central Nervous System Diffuse B-Cell Lymphoma

Preliminary Data of a Single-Arm, Phase II Study of Orelabrutinib with/without Rituximab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma after BTK Inhibitor Therapy

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

The Primary Results of R-MTO Regimen (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib) As the First-Line Induction Therapy Followed By Autologous Stem Cell Transplantation in Newly Diagnosed Primary Central Nervous System Lymphoma

Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Idiopathic Multicentric Castleman Disease: A Single-Center, Retrospective Study

A Prospective Study of Orelabrutinib plus Obinutuzumab (O2) in Treatment-naïve Marginal Zone Lymphoma (MZL): Preliminary Analysis on Efficacy and Safety (Abstract No.: 815MO)

Orelabrutinib-based Regimens in Chronic Lymphocytic Leukemia with Comorbidities: A Real-World Study (Abstract No.: 840P)

Efficacy and Safety of Orelabrutinib plus R-CHOP-like Regimens for Treatment-naïve Diffuse Large B-cell Lymphoma with Double Expression (Abstract No.: 819P)

Fixed-duration Orelabrutinib plus Bendamustine and Rituximab versus Continuous Bruton Tyrosine Kinase Inhibitor (BTKi) in Treatment-naïve Chronic/small Lymphocytic Leukemia (CLL/SLL): A Multicenter, Nonrandomized, Pragmatic Clinical trial (Abstract No.: 846TiP)

Orelabrutinib combined with Rituximab for the Treatment of Elderly patients with newly diagnosed non-GCB diffuse large B-cell lymphoma (DLBCL) under the guidance of genetic subtype: A prospective, multicenter, single-arm, response-adaptive clinical study (Origin) (Abstract No.: 844TiP)

Subcutaneous ICP-B02 (CM355) , a Novel Bispecific CD20/CD3 Antibody Showed Promising Efficacy and Favorable Safety Profile in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Dose-Escalation Data from a Phase I/II Trial

A Phase II, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Tafasitamab Combined with Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Preliminary Safety and Efficacy Data from Patients with Relapsed or Refractory B-Cell Malignancies Treated with ICP-248, a Novel BCL2 Inhibitor

Orelabrutinib, Rituximab and High-Dose Methotrexate (HD-MTX) in Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis on Efficacy and Safety

Different Subtype of DLBCL Patients Treated with R-Chop (Like) Plus Orelabrutinib Regimen: A Real-World Study

Phase II Study of Orelabrutinib, Rituximab and Thiotepa (ORT) Combined with or without High-Dose MTX Therapy in Patients with Primary CNS Lymphoma

Real-World Analysis of Orelabrutinib in Patients (PTS) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (CWCLL-001 Study)

Orelabrutinib in Patients with Indolent Non-Hodgkin Lymphoma (INHL) Intolerant to Prior Bruton Tyrosine Kinase Inhibitors (BTKI): Preliminary Results from a Phase 2 Study

Real-World Outcomes of Orelabrutinib as First-Line Treatment in CLL/SLL: A Multicenter Study

Orelabrutinib in Combination with PD-1 Inhibitor Inrefractory or Relapsed Primary CNS Lymphoma

The Primary Results of R-MTO Regimen (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib) as the First-Line Induction Therapy in Newly Diagnosed Primary Central Nervous System Lymphoma

Orient Study: Orelabrutinib Addition to R-Chop-Like Regimen Adapted to Response in Treatment-Naïve Non-GCB DLBCL

Orelabrutinib-Lenalidomide-Rituximab in Patients with Untreated Mantle Cell Lymphoma (MCL): Updated Results of Themulticenter, Phase II Polaris Study

Efficacy and Safety of a Highly Selective Oral TYK2/JAK1 Inhibitor, ICP-332, in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase II, Randomized, Placebo-Controlled Trial

A Prospective Multicenter Phase II Study of Orelabrutinib-Lenalidomide-Rituximab (OLR) in Patients with Untreated Mantle Cell Lymphoma (MCL) in China (POLARIS Study): Preliminary Analysis on Efficacy, Safety, Mutation Spectrum and Impact of Mutation Profiling on Treatment Responses

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results

Preliminary safety, pharmacological and efficacy data from patients with relapsed or refractory B-cell malignancies treated with the ICP-248, a next generation BCL2 inhibitor

Effectiveness and Safety of Orelabrutinib Combined with Rituximab As First-Line Treatment in Marginal Zone Lymphoma

Orelabrutinib plus R-CHOP regimen in treatment-naïve patients with TP53-mutated diffuse large B-cell lymphoma (DLBCL)

Efficacy and safety of orelabrutinib- containing TORM regime as first-line therapy in primary central nervous system lymphoma (PCNSL): a retrospective analysis

Preliminary Results of Phase 1 Trial of Orelabrutinib in Combination with Rituximab, Methotrexate, and Dexamethasone in Patients with Newly Diagnosed Primary CNS Lymphoma Implementing Bayesian Design for Dose-Seeking

Effectivness and Safety of Orelabrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Retrospective, Real-World Study in China

Pomalidomide, Rituximab, Orelabrutinib, and Minichop-like (PRO-miniCHOP) in Elderly Patients with Newly Diagnosed Diffuse Large-B Cell Lymphoma: Preliminary Results from a Phase II Study

Orelabrutinib, an Irreversible Inhibitor of Bruton's Tyrosine Kinase, for Treatment of Primary Immune Thrombocytopenia: Results of a Randomized, Open-Label Phase II Study

Orient Study: Regimen of Orelabrutinib plus R-CHOP-Like for Patients with Newly Diagnosed Untreated Non-GCB DLBCL

Preliminary Findings of a Phase II Study of Chemo-Free Combination of Pomalidomide, Orelabrutinib, Rituximab with Sequential High-Dose Methotrexate in Newly Diagnosed Primary CNS Lymphoma

Orelabrutinib, a New-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma

Orelabrutinib-Lenalidomide-Rituximab (OLR) in Patients with Untreated Mantle Cell Lymphoma (MCL): A Prospective, Multicenter, Single-Arm Phase 2 Polaris Study in China

Combination of BTK Inhibitor Orelabrutinib, Anti-CD19 Antibody Tafasitamab, and IMiD Lenalidomide for the Treatment of B Cell Malignancies (Abstract Number: 4013)

Preclinical Development of SHP2 Allosteric Inhibitor ICP-189 (Abstract Number: 4012)

ICP-490 Is a Highly Potent and Selective IKZF1/3 Degrader with Robust Anti-Tumor Activities against Multiple Myeloma and Non-Hodgkin’s Lymphoma (Abstract Number: 3427)

Gunagratinib, a Highly Selective Irreversible FGFR Inhibitor, in Patients with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma Harboring FGFR Pathway Alterations: A Phase IIa Dose-Expansion Study

Orelabrutinib, Rituximab, and High-Dose Methotrexate (HD-MTX) in Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis on Efficacy, Safety, and Biomarker

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of Orelabrutinib Plus R-CHOP Versus Placebo Plus R-CHOP in Treatment-Naïve Patients with Mcd Subtype Diffuse Large B-Cell Lymphoma

Orelabrutinib plus RCHOP for Previously Untreated Non-Germinal Center B Cell-like (GCB) Diffuse Large B Cell Lymphoma (DLBCL) Patients with Extranodal Disease

Preliminary Results of a Phase II Study of Orelabrutinib in Combination with Anti-PD-1 Monoclonal Antibody in Refractory or Relapsed Primary CNS Lymphoma

ICP-723 Is a Potent Pan-TRK Inhibitor with Robust Anti-Tumor Activities against Wild-Type and Acquired Drug-Resistant Mutations of NTRK Fusions

Phase I Results of Gunagratinib (ICP-192), a Highly Selective Irreversible FGFR 1-4 Inhibitor in Patients with Head and Neck Cancer Harboring FGF/FGFR Gene Aberrations

Safety, Pharmacokinetics (PK), and Clinical Efficacy of ICP-723, a Highly Selective Next-Generation Pan-TRK Inhibitor, in Patients with Solid Tumor

Efficacy and Safety of Orelabrutinib in Diffuse Large B-cell Lymphoma: A Real-World Analysis

Orelabrutinib, An Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), for the Treatment of Systemic Lupus Erythematosus (SLE): Results of A Randomized, Double-Blind, Placebo-Controlled, Phase IB/IIA Dosefinding Study (Abstract Number: LB0005)

Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patients

Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updated Long Term Results of Phase II Study

Orelabrutinib, a Selective Bruton's Tyrosine Kinase (BTK) Inhibitor in the Treatment of Primary Immune Thrombocytopenia (ITP)

Phase I Result of ICP-192 (Gunagratinib), a Highly Selective Irreversible FGFR Inhibitor, in Patients with Advanced Solid Tumors Harboring FGFR Pathway Alterations

Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study

Updated Results from the Phase II Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia

Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies

Orelabrutinib, a Potent and Selective Bruton's Tyrosine Kinase Inhibitor with Superior Safety Profile and Excellent PK/PD Properties

Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study

Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia